EYPT EyePoint Pharmaceuticals Inc.

Ticker Search

1.86

+0.01 (+0%)

Previous Close 1.85

Open 1.85

Price To Book 6.87

Market Cap 197,182,404

Shares 106,297,792

Volume 48,314

Short Ratio

Av. Daily Volume 309,215

NewsSee all news

09 September 2019 EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting
WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014

Iluvien

Diabetic macular edema

FDA approval announced October 15, 2018.

YUTIQ

Non-infectious uveitis

12/31/2019

sNDA filing due 2019 for 6-month formulation.

Yutiq

Non-infectious uveitis

09 September 2019 EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting
WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today